TP53 and colorectal carcinoma: The HDAC2 impact on DNA-damaging agents resistance has also been established for colorectal adenocarcinoma CRC cell lines with different statuses of TP53 (TP53-mutated, TP53-WT, and TP53-deficient cells) by determining the pharmacological effect between them and SAHA or VPA.